The Joint Corp.

NasdaqCM:JYNT 株式レポート

時価総額:US$120.8m

Joint 過去の業績

過去 基準チェック /36

Jointの収益は年間平均-57.6%の割合で減少していますが、 Healthcare業界の収益は年間 増加しています。収益は年間4% 13.9%割合で 減少しています。 Jointの自己資本利益率は8.7%であり、純利益率は2.4%です。

主要情報

-57.63%

収益成長率

-58.26%

EPS成長率

Healthcare 業界の成長8.50%
収益成長率-13.92%
株主資本利益率8.65%
ネット・マージン2.37%
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

分析記事 Feb 11

Estimating The Fair Value Of The Joint Corp. (NASDAQ:JYNT)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Joint fair value estimate is US$10.07 Current share price of...
Seeking Alpha Apr 29

The Joint Corp. Has Shown Good Momentum For Future Returns (Rating Upgrade)

Summary JYNT's Q4 results showed strong growth, with revenue from continuing operations up 14% YOY and system-wide sales growth at 9%, indicating business resilience. New CEO's vision and initiatives, including dynamic pricing and a mobile app, are promising, despite initial skepticism about his lack of industry experience. The refranchising strategy will transition JYNT to a royalty-based model by 2025, potentially boosting profitability with fewer assets and lower SG&A costs. Despite macroeconomic risks and potential litigation, JYNT's strong brand equity and growth runway make it a buy, with significant future cash flow potential. Read the full article on Seeking Alpha
分析記事 Mar 20

There's Reason For Concern Over The Joint Corp.'s (NASDAQ:JYNT) Price

When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...
分析記事 Jan 22

The Joint Corp.'s (NASDAQ:JYNT) Intrinsic Value Is Potentially 59% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Joint fair value estimate is US$18.10 Joint's US$11.40 share...
分析記事 Sep 14

The Joint Corp.'s (NASDAQ:JYNT) Price Is Out Of Tune With Revenues

There wouldn't be many who think The Joint Corp.'s ( NASDAQ:JYNT ) price-to-sales (or "P/S") ratio of 1.5x is worth a...
分析記事 Aug 05

The Joint Corp. (NASDAQ:JYNT) Shares Could Be 22% Above Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Joint fair value estimate is US$10.40 Joint's US$12.73 share...
分析記事 Jul 17

Investors Could Be Concerned With Joint's (NASDAQ:JYNT) Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
分析記事 May 04

Optimistic Investors Push The Joint Corp. (NASDAQ:JYNT) Shares Up 26% But Growth Is Lacking

The Joint Corp. ( NASDAQ:JYNT ) shares have continued their recent momentum with a 26% gain in the last month alone...
分析記事 Mar 10

The Joint Corp.'s (NASDAQ:JYNT) Share Price Not Quite Adding Up

With a median price-to-sales (or "P/S") ratio of close to 1x in the Healthcare industry in the United States, you could...
分析記事 Feb 12

Returns Are Gaining Momentum At Joint (NASDAQ:JYNT)

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...
分析記事 Jun 17

Joint (NASDAQ:JYNT) Shareholders Will Want The ROCE Trajectory To Continue

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
分析記事 Jan 04

Joint's (NASDAQ:JYNT) Returns On Capital Are Heading Higher

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
分析記事 Oct 27

Does Joint (NASDAQ:JYNT) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha Oct 17

The Joint Corp. Can Relieve You From High Inflation Pain

Summary The Joint Corp. is the largest provider of chiropractic care in the U.S., and its stock provides great upside potentials from secular healthcare trends. The company is a value compounder with significant growth opportunities and strong economic moats. Steep price decline from unsustainably high price a year ago as well as recent bear market made The Joint Corp.'s stock price depressed, which gives a good entry point. The Joint Corp. is well positioned to withstand the worrying macroeconomic factors including recent rising interest rates, energy crisis, and geopolitical risks. 1. Introduction Modern people suffer from chronic muscle pain due to the habit of sitting for a long time at home or work. They use a variety of methods including drug treatments and manual therapy to relieve pain and stay healthy. The Joint Corp. (JYNT) provides the solution for chiropractic care. Licensed practitioners conduct adjustments and offer an excellent alternative to pain relief measures for patients who are concerned about the side effects of drug treatment. Furthermore, the company is creating great value for consumers, business partners, and the company itself by improving inefficiencies and inconveniences that exist for a long time in the chiropractic industry through its unique and innovative business models. 2. Investment thesis First of all, The company is in a large and growing industry, and its current market share is still small, leaving room for further growth in the future. Second, it possesses several characteristics of a quality business, including the first mover advantages, an ability to sustain high returns on invested capital, and conservative balance sheets. Lastly, the current share price has significant upside potential in consideration of the company's growth potential and quality. 2-1) Growth The chiropractic industry is big and growing. Chiropractic care helps individuals with various pains, particularly back pain. According to a company filing which refers to the bureau of labor statistics and IBIS world chiropractors market research, people in the U.S. spends about $90 billion on back pain and about $18 billion on chiropractic services. The company's market share (The Joint Q2 22 Investor Presentation) Nevertheless, the company's share is only a fraction of the overall market. In other words, the company has ample room for further growth in this market in the future. As shown in the picture above, the market is highly fragmented. 96% of the market is composed of sole practitioners, and only 4% represent multi-unit operators like JYNT. Comparing multi-unit operators, the company has a market share of half, indicating it has competitive advantages. 2-2) Competitive advantages The company is innovative in the way it practices its business in a highly inefficient industry. It differentiates itself from its competitors by using a private pay, non-insurance, cash-based model. Innovative value proposition (The Joint Q2 22 Investor Presentation) The company delivers convenient, appointment-free chiropractic care in retail locations to its customers or patients. Also it provides great values to its employees and business partners like chiropractic practitioners, including higher salaries and no hassles with administration, which eventually gives more time to improve their core skills. Peer group of the company (The Joint Q2 22 Investor Presentation) The company increases its value based on its competitive advantages as well. First of all, it maximizes the first mover advantages. As seen above, the company has the largest share among multi-unit operators and is widening the gap. Although Airrosti, HealthSource Chiropractic, and ChiroOne Wellness Centers are comparable in scale, they are declining in contrast to the company's increasing number of clinics since 2017. Also, they mostly depend on insurance-based models. Competitors that adopt the same cash-only model as JYNT are 11 companies but cannot match the company in scale. Eight of them just operate fewer than 12 clinics. Second, the company directly operates the clinic or recruits franchisees. Franchising gives it a great competitive advantage. It reduces capital expenditures because franchisees finance a part of the investment. It also generates high returns for the company by receiving fees such as royalties based on sales. Clinic economics (The Joint Q2 22 Investor Presentation) It is good for franchisees to participate in the franchise of the Joint. Its clinics show great unit economics because the initial investment is small. All they need is a decent-sized retail space and a minimum of two people to run a clinic including WC (Wealth Coordinator) and DC (Chiropractic Doctor). There is no inventory risk like in other retailers. Therefore, The period to reach breakeven point is quite short and it takes about eight months. Business segments ( The Joint Q2 22 Investor Presentation) The company's current portfolio consists of 85% franchised and 15% company-owned clinics. It needs to rapidly increase clinics to gain wide brand awareness across the country. However, the proportion of franchising will increase later when it enters a certain maturity stage. I expect it to take three years, or when it operates more than 1,000 clinics. Then, profitable business segments will more contribute to the company's overall profitability, which will greatly increase the company's value. Credit Metrics (Created by the author using company reports) Lastly, the company maintains a conservative and strong balance sheets. It can withstand the current economic uncertainty and unfavorable macroeconomic factors including rising interest rates, high energy prices, intensifying geopolitical risks. The company has a cash balance greater than the total debt amount, protecting itself from refinancing risks and using cash for lucrative reinvestment opportunities. Also its services are by nature tech-proof unlike other retail companies. 3. Valuation The company's core value driver is the franchise clinic segment. Franchise clinics generate strong and stable free cash flows because they have better profitability and higher capital turnover than company-owned clinics. My valuation assumptions are as follows: the target number of clinics open for the next 10 years is 2,000. I assume the proportion of franchise clinics to increase from 85% to 95%. The Joint's system-wide sales per store is expected to grow 3% per annum, and franchise fee margin royalties are set at 12%. Tax rates are 27.0% and the cost of capital is about 9.0%. Using these assumptions, I estimate the company's future free cash flows as shown below. DCF (Created by the author using company reports) My valuation model implies the company's terminal EV/EBITDA multiple at about 15 times. The calculated value per share is about $25 after considering a 5.0% probability of failure. It indicates the current price is undervalued and has about 40% upside potential. Value per share (Created by the author) I examined the distribution of intrinsic value per share by conducting a sensitivity analysis of main value drivers which include target clinics open, store sales growth rates, and the proportion of franchise clinics. I found that falling short of the target number of stores had a significant impact on the value. If the number of stores falls below 1,350 over the next 10 years, the current stock price has no upside potential. Conversely, sales growth per store does not seem to have a greater impact than other factors. Finally, if the franchise store ratio remains the same or below, the stock price is likely to fall more. It is because the company has to grow by doing a low-margin capital-heavy company-owned clinics, not by profitable franchise clinics. Sensitivity analysis of the main value drivers (Created by the author) 4. Risks The high inflation environment had an unfavorable effect on the company's profitability. Labor cost is one of the main costs required to run a clinic. Recently the company raised the salaries of its clinic employees. As a result, the period to reach Breakeven point increased from six months to eight months.

収支内訳

Joint の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:JYNT 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 26571430
31 Dec 25550430
30 Sep 25540410
30 Jun 2553-1410
31 Mar 2553-2420
31 Dec 2452-2410
30 Sep 24-3-15-80
30 Jun 2414-1570
31 Mar 2431-13200
31 Dec 2347-11350
30 Sep 231152950
30 Jun 231124920
31 Mar 231073900
31 Dec 221011840
30 Sep 22950820
30 Jun 22892760
31 Mar 22855690
31 Dec 21808620
30 Sep 217618550
30 Jun 217017500
31 Mar 216315460
31 Dec 205913440
30 Sep 20564430
30 Jun 20533410
31 Mar 20513400
31 Dec 19483370
30 Sep 19452350
30 Jun 19412330
31 Mar 19391310
31 Dec 18370300
30 Sep 1834-1280
30 Jun 1831-1260
31 Mar 1828-2240
31 Dec 1725-3230
30 Sep 1724-9230
30 Jun 1723-11250
31 Mar 1722-13260
31 Dec 1621-15260
30 Sep 1619-13260
30 Jun 1617-12240
31 Mar 1616-10210
31 Dec 1514-9190
30 Sep 1512-8150
30 Jun 1510-7120

質の高い収益: JYNTは 高品質の収益 を持っています。

利益率の向上: JYNT過去に利益を上げました。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: JYNT過去 5 年間で収益を上げており、収益は年間-57.6%増加しています。

成長の加速: JYNTは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: JYNT昨年収益を上げたため、昨年の収益成長をHealthcare業界 ( 17% ) と比較することは困難です。


株主資本利益率

高いROE: JYNTの 自己資本利益率 ( 8.7% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/05/22 13:27
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

The Joint Corp. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Jeffrey Van SinderenB. Riley Securities, Inc.
Jeremy HamblinCraig-Hallum Capital Group LLC
Linda Bolton-WeiserD.A. Davidson & Co.